Last reviewed 2026-04-20 · How we verify

Ticlid (TICLOPIDINE)

Ticlid (Ticlopidine) is a small molecule platelet aggregation inhibitor that targets the alpha-2B adrenergic receptor. Originally developed by, it was approved by the FDA in 1991 for indications including cerebrovascular occlusion, percutaneous coronary intervention, prevention of cerebral thrombosis, and subacute stent thrombosis prevention. Ticlid is now off-patent with 8 generic manufacturers. Key safety considerations include potential hematologic and gastrointestinal side effects. As a platelet aggregation inhibitor, Ticlid works by blocking the action of adenosine diphosphate (ADP) on platelets, thereby preventing platelet activation and aggregation.

At a glance

Approved indications

• Cerebrovascular Occlusion
• Percutaneous coronary intervention
• Prevention of Cerebral Thrombosis
• Subacute Stent Thrombosis Prevention

Common side effects

• Any Events
• Diarrhea
• Nausea
• Dyspepsia
• Rash
• GI Pain
• Neutropenia
• Purpura
• Vomiting
• Flatulence
• Pruritus
• Dizziness

Key clinical trials

• The Effect and Safety of Combined Anti-platelet Treatment in Acute Ischemic Stroke Due to Large Artery Atherosclerosis (PHASE4)
• Clopidogrel vs. Aspirin for Cardiovascular Risk Reduction in Patients With S. Aureus Bacteremia (PHASE4)
• Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis (PHASE3)
• Tailoring Bleeding Reduction Approaches in Patients Undergoing PCI (PHASE4)
• Testing a New Treatment Strategy to Improve Secondary Stroke Prevention for Older Adults: The STROKE75+ Trial (PHASE3)
• Efficacy and Safety of Tirofiban for Patients With BAD (BRANT) (PHASE3)
• A Study to Evaluate Safety and PK of Multiple Doses of LT3001 Drug Product and Drug-drug Interaction in Healthy Subjects (PHASE1)
• The Switching Antiplatelet-9 (SWAP-9) Study (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.